RecruitingPhase 1NCT07099118

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Doses of HEC169584 Capsules and the Effect of Food on Its Pharmacokinetics in Healthy Subjects

Sponsor

Sunshine Lake Pharma Co., Ltd.

Enrollment

96 participants

Start Date

Sep 3, 2025

Study Type

INTERVENTIONAL

Conditions

Non Alcoholic Steatohepatitis

Summary

The safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics study of HEC169584 capsules in healthy subjects .

Eligibility

Min Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HEC169584 capsule and a drug called placebo for people with non alcoholic steatohepatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHEC169584 capsule

Each dose of HEC83518 will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

DRUGplacebo

The placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.

Locations(1)

No. 49, Huayuan North Road, Haidian District, Beijing Municipality

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07099118

Related Trials

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT054637961 location

Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

NCT038840751 location

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

NCT061388212 locations

Identification of Liver Fibrosis Biomarkers

NCT068199172 locations

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

NCT056231501 location